1)Mizuki N, Meguro A, Ota M et al:Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nature genetics 42:703-706, 2010
2)Takeuchi M, Kastner DL, Remmers EF:The immunogenetics of Behcet's disease:a comprehensive review. Journal of autoimmunity 64:137-148, 2015
3)de Menthon M, Lavalley MP, Maldini C et al:HLA-B51/B5 and the risk of Behcet's disease:a systematic review and meta-analysis of case-control genetic association studies. Arthritis and rheumatism 61:1287-1296, 2009
4)Takeuchi M, Mizuki N, Meguro A et al:Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behcet's disease susceptibility. Nature genetics 49:438-443, 2017
5)Kaburaki T, Araki F, Takamoto M et al:Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behcet's disease. Graefes Arch Clin Exp Ophthalmol 248:709-714, 2010
6)Meguro A, Ishihara M, Petrek M et al:Genetic control of CCL24, POR, and IL23R contributes to the pathogenesis of sarcoidosis. Commun Biol 3:465, 2020
7)Cantarini L, Vitale A, Scalini P et al:Anakinra treatment in drug-resistant Behcet's disease:a case series. Clinical rheumatology 34:1293-1301, 2015
8)Fabiani C, Vitale A, Emmi G et al:Interleukin(IL)-1 inhibition with anakinra and canakinumab in Behcet's disease-related uveitis:a multicenter retrospective observational study. Clinical rheumatology 36:191-197, 2017
9)Atienza-Mateo B, Calvo-Rio V, Beltran E et al:Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet's disease:multicentre retrospective study. Rheumatology(Oxford, England)57:856-864, 2018
10)Mirouse A, Barete S, Monfort JB et al:Ustekinumab for Behçet's disease. Journal of autoimmunity 82:41-46, 2017
11)Hueber W, Patel DD, Dryja T et al:Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2:52ra72, 2010
12)Dick AD, Tugal-Tutkun I, Foster S et al:Secukinumab in the treatment of noninfectious uveitis:results of three randomized, controlled clinical trials. Ophthalmology 120:777-787, 2013
13)Letko E, Yeh S, Foster CS et al:Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology 122:939-948, 2015